



EBMT Activity Survey 2017

683 Teams
41,100 Patients
45,418 Transplants
49 Countries

[For internal use only.](#)

For any other use, please contact Helen Baldomero for permission: helen.baldomero@usb.ch

www.ebmt.org

EBMT Activity Survey in 2017: Patient and transplant numbers

Indication	Allogeneic HSCT	Autologous HSCT	Total
1st allo/1 st auto HSCT	17,155	23,945	41,100
Additional HSCT	1,126	3,192	4,318
TOTAL	18,281	27,137	45,418

Teams: 683 (of 710)

Countries reporting: 49

EBMT Activity Survey in 2017:

Donor type and stem cell source: all transplants

Donor type	Stem Cell Source			Total
	BM	PBSC	Cord	
HLA-id sibling	1,420	4,411	33	5,864
Haplo-identical	708	1,981	n.a.	2,689
Other family	89	212	5	306
Syngeneic	n.a.	n.a.	n.a.	21
Unrelated	1,492	7,579	330	9,401
Allogeneic	3,709	14,204	368	18,281
Autologous	112	27,022	3	27,137


EBMT Activity Survey 2017:

Main indications

Indication	Allogeneic 1 st HSCT	Autologous 1 st HSCT	Total
Myeloid (AML, CML, MDS/MPN)	9,772	375	10,147
Lymphoid (ALL, CLL, HL, NHL)	4,630	8,781	13,411
Plasma cell disorder	385	12,692	13,077
Solid tumor	36	1,571	1,607
Non-malignant disorders	2,173	494	2,667
<i>bone marrow failure</i>	802	1	803
Other	159	32	191
Total Patients	17,155	23,945	41,100


Allogeneic HSCT in Europe 2017

1st HSCT




Autologous HSCT in Europe 2017

1st HSCT




HSCT Activity in Europe 1990-2017: Transplant type 1st HSCT




HSCT Activity in Europe 1990-2017:

Main indications: allogeneic 1st. HSCT




HSCT Activity in Europe 1990-2017:

Main indications: autologous 1st. HSCT






HSCT Activity in Europe 1990-2017: donor origin: 1st. HSCT



HSCT - rates in Europe 2017

N. allogeneic transplants
per 10 million population



HSCT - rates in Europe 2017

N. autologous transplants
per 10 million population

